

ATTACHMENT: INCREASED DISPENSING QUANTITIES - LIST OF MEDICINES

This attachment includes the medicines recommended as suitable by the PBAC for listing on the PBS with increased dispensed quantities. Please note that some strengths, forms, and indications of a medicine may not be included in the recommended list below. The PBS item codes in this document are those listed on the PBS Schedule effective 1 December 2022.

Table 1: PBS Section 85 medicines found suitable by the PBAC for listing with additional item codes for increased dispensed quantities (304 medicines). This list was correct at the time the PBAC made recommendations for increased dispensed quantities (December 2022) but due to ongoing monthly PBS Schedule updates and changes, some PBS items found suitable may no longer appear in the PBS Schedule.

Table 2: PBS Section 85 medicines currently available under the *12 month repeat measure* found suitable for amendment in accordance with the PBAC recommendations for increased dispensed quantities (21 medicines).

TABLE OF CONTENTS (MEDICINES ARRANGED ALPHANUMERICALLY WITHIN BODY SYSTEM GROUPS):

HOW TO USE THIS DOCUMENT	page 2
TABLE 1:	page 6
1.1 ALIMENTARY TRACT & METABOLISM	page 6
1.2 BLOOD	page 16
1.3 CARDIOVASCULAR SYSTEM	page 17
1.4 DERMATOLOGICALS	page 27
1.5 HORMONAL MODULATORS	page 28
1.6 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	page 31
1.7 ANTIINFECTIVES FOR SYSTEMIC USE	page 33
1.8 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	page 34
1.9 MUSCULO-SKELETAL SYSTEM	page 36
1.10 NERVOUS SYSTEM	page 37
1.11 RESPIRATORY SYSTEM	page 45
1.12 SENSORY ORGANS	page 51
1.13 VARIOUS	page 56
TABLE 2:	page 57
2.1 AMENDED LISTINGS	page 57


HOW TO USE THIS DOCUMENT

This measure includes an extensive list of medicines.


To find out if a specific medicine is included in this measure, follow ONE of TWO methods detailed below:

METHOD ONE:

1. Hold the 'Ctrl' key (for Windows) or 'Command' key (for Mac) key while pressing the 'F' key on the keyboard.
2. The following search box should appear in the document:
 - a. Use the mouse to click on the 'Find' line within this box:



- b. Type in the medicine name or brand then press 'Next'.



3. The document will highlight the medicine or brand that was typed in 'Find'.

Pharmaceutical Benefits Scheme (PBS) - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Brand	Indication (M=multiple, blank=Unrestricted)
atenolol 50 mg tablet	APO-Atenolol Atenolol Amneal Atenolol GH Atenolol Sandoz Atenolol-GA Chem mart Atenolol Noten Tenolten 50 Tensig Terry White Chemists Atenolol Tenormin	
atenolol 50 mg/10 mL oral liquid	Atenolol-AFT	For patients who are unable to take a solid dose form of atenolol.
atorvastatin 10 mg tablet	APO-Atorvastatin Atorvachol Atorvastatin Amneal Atorvastatin GH Atorvastatin SZ Atorvastatin Sandoz Blooms the Chemist Atorvastatin Chem mart Atorvastatin Lipitor Lorstat 10 Pharmacor Atorvastatin Terry White Chemists Atorvastatin Torvastat 10 Trovas	

Find ✕

atorvastatin

Previous Next



4. If no matches were found within the document, it is likely that the medicine is not included in this measure.



Pharmaceutical Benefits Scheme (PBS) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

TABLE 1:

The following PBS medicines/item codes were found suitable by the PBAC for listing with additional item codes for increased dispensed quantities.

1.1 ALIMENTARY TRACT & METABOLISM

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
acarbose 100 mg tablet, 90	8189B		
acarbose 50 mg tablet, 90	8188Y		
alogliptin 12.5 mg + metformin hydrochloride 1 g tablet, 56	10035		
alogliptin 12.5 mg + metformin hydrochloride 500 mg tablet, 56	10033		
alogliptin 12.5 mg + metformin hydrochloride 850 mg tablet, 56	10032		
alogliptin 12.5 mg tablet, 28	2933J		
alogliptin 25 mg tablet, 28	2986E		
alogliptin 6.25 mg tablet, 28	2944Y		
balsalazide sodium 750 mg capsule, 280	11351K		Ulcerative colitis
bisacodyl 10 mg suppository, 10	1260H		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
bisacodyl 10 mg suppository, 12	1258F		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
bisacodyl 5 mg enteric tablet, 200	1259G		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
calcitriol 0.25 microgram capsule, 100	2502Q		M - Established osteoporosis, Hypocalcaemia, Hypoparathyroidism, Hypophosphataemic rickets, Vitamin D-resistant rickets
calcium carbonate 1.25 g (calcium 500 mg) chewable tablet, 120	11726E		Hyperphosphataemia



METHOD TWO:

1. If you know which 'Body System' your medicine belongs in, *click* on the corresponding 'Body System' from the contents page of this document.

TABLE OF CONTENTS (MEDICINES ARRANGED ALPHANUMERICALLY WITHIN BODY SYSTEM GROUPS):

HOW TO USE THIS DOCUMENT	page 2
TABLE 1:	
1.1 ALIMENTARY TRACT & METABOLISM	page 6
1.2 BLOOD	page 16
1.3 CARDIOVASCULAR SYSTEM	page 17
1.4 DERMATOLOGICALS	page 27
1.5 HORMONAL MODULATORS	page 28
1.6 SYSTEMIC HORMONAL PREPARATIONS, EXL. SEX HORMONES AND INSULINS	page 31
1.7 ANTIINFECTIVES FOR SYSTEMIC USE	page 33
1.8 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	page 34
1.9 MUSCULO-SKELETAL SYSTEM	page 36
1.10 NERVOUS SYSTEM	page 37
1.11 RESPIRATORY SYSTEM	page 45
1.12 SENSORY ORGANS	page 51
1.13 VARIOUS	page 56
TABLE 2:	
2.1 AMENDED LISTINGS	page 57

2. The document will go to the corresponding 'Body System' page, from there, the medications are ordered alphanumerically.

TABLE 1:

The following PBS medicines/item codes were found suitable by the PBAC for listing with additional item codes for increased dispensed quantities.

1.1 ALIMENTARY TRACT & METABOLISM

<i>Medicine (strength & form)</i>	<i>Item Code</i>	<i>Brand</i>	<i>Indication (M=multiple, blank=Unrestricted)</i>
acarbose 100 mg tablet, 90	8189B		
acarbose 50 mg tablet, 90	8188Y		
alogliptin 12.5 mg + metformin hydrochloride 1 g tablet, 56	10035E		Diabetes mellitus type 2
alogliptin 12.5 mg + metformin hydrochloride 500 mg tablet, 56	10033C		Diabetes mellitus type 2
alogliptin 12.5 mg + metformin hydrochloride 850 mg tablet, 56	10032B		Diabetes mellitus type 2
alogliptin 12.5 mg tablet, 28	2933J		Diabetes mellitus type 2
alogliptin 25 mg tablet, 28	2986E		Diabetes mellitus type 2
alogliptin 6.25 mg tablet, 28	2944Y		Diabetes mellitus type 2
balsalazide sodium 750 mg capsule, 280	11351K		Ulcerative colitis
bisacodyl 10 mg suppository, 10	1260H		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
bisacodyl 10 mg suppository, 12	1258F		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
bisacodyl 5 mg enteric tablet, 200	1259G		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
calcitriol 0.25 microgram capsule, 100	2502Q		M - Established osteoporosis, Hypocalcaemia, Hypoparathyroidism, Hypophosphataemic rickets, Vitamin D-resistant rickets
calcium carbonate 1.25 g (calcium 500 mg) chewable tablet, 120	11726E		Hyperphosphataemia
calcium carbonate 1.5 g (calcium 600 mg) tablet, 240	3117C		Hyperphosphataemia

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
dapagliflozin 10 mg + metformin hydrochloride 1 g modified release tablet, 28	10515K		Diabetes mellitus type 2
dapagliflozin 10 mg + metformin hydrochloride 1 g modified release tablet, 28	11313K		Diabetes mellitus type 2
dapagliflozin 10 mg + metformin hydrochloride 500 mg modified release tablet, 28	10516L		Diabetes mellitus type 2
dapagliflozin 10 mg + metformin hydrochloride 500 mg modified release tablet, 28	11270E		Diabetes mellitus type 2
dapagliflozin 10 mg tablet, 28	10011X		Diabetes mellitus type 2
dapagliflozin 10 mg tablet, 28	11291G		Diabetes mellitus type 2
dapagliflozin 10 mg tablet, 28	12823X		Chronic heart failure
dapagliflozin 5 mg + metformin hydrochloride 1 g modified release tablet, 56	10510E		Diabetes mellitus type 2
dapagliflozin 5 mg + metformin hydrochloride 1 g modified release tablet, 56	11300R		Diabetes mellitus type 2
dulaglutide 1.5 mg/0.5 mL injection, 4 x 0.5 mL pen devices	11364D		Diabetes mellitus type 2
empagliflozin 10 mg + linagliptin 5 mg tablet, 30	11269D		Diabetes mellitus type 2
empagliflozin 10 mg + linagliptin 5 mg tablet, 30	11310G		Diabetes mellitus type 2
empagliflozin 10 mg tablet, 30	10206E		Diabetes mellitus type 2
empagliflozin 10 mg tablet, 30	11314L		Diabetes mellitus type 2
empagliflozin 10 mg tablet, 30	12918X		Chronic heart failure
empagliflozin 12.5 mg + metformin hydrochloride 1 g tablet, 60	10640B		Diabetes mellitus type 2
empagliflozin 12.5 mg + metformin hydrochloride 1 g tablet, 60	10677Y		Diabetes mellitus type 2
empagliflozin 12.5 mg + metformin hydrochloride 500 mg tablet, 60	10633P		Diabetes mellitus type 2
empagliflozin 12.5 mg + metformin hydrochloride 500 mg tablet, 60	10639Y		Diabetes mellitus type 2
empagliflozin 25 mg + linagliptin 5 mg tablet, 30	11298P		Diabetes mellitus type 2
empagliflozin 25 mg + linagliptin 5 mg tablet, 30	11303X		Diabetes mellitus type 2

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
empagliflozin 25 mg tablet, 30	10202Y		Diabetes mellitus type 2
empagliflozin 25 mg tablet, 30	11281R		Diabetes mellitus type 2
empagliflozin 5 mg + metformin hydrochloride 1 g tablet, 60	10627H		Diabetes mellitus type 2
empagliflozin 5 mg + metformin hydrochloride 1 g tablet, 60	10649L		Diabetes mellitus type 2
empagliflozin 5 mg + metformin hydrochloride 500 mg tablet, 60	10626G		Diabetes mellitus type 2
empagliflozin 5 mg + metformin hydrochloride 500 mg tablet, 60	10650M		Diabetes mellitus type 2
ertugliflozin 15 mg + sitagliptin 100 mg tablet, 28	11578J		Diabetes mellitus type 2
ertugliflozin 15 mg + sitagliptin 100 mg tablet, 28	11583P		Diabetes mellitus type 2
ertugliflozin 15 mg tablet, 28	11570Y		Diabetes mellitus type 2
ertugliflozin 15 mg tablet, 28	11571B		Diabetes mellitus type 2
ertugliflozin 2.5 mg + metformin hydrochloride 1 g tablet, 56	11564P		Diabetes mellitus type 2
ertugliflozin 2.5 mg + metformin hydrochloride 1 g tablet, 56	11581M		Diabetes mellitus type 2
ertugliflozin 2.5 mg + metformin hydrochloride 500 mg tablet, 56	11575F		Diabetes mellitus type 2
ertugliflozin 2.5 mg + metformin hydrochloride 500 mg tablet, 56	11584Q		Diabetes mellitus type 2
ertugliflozin 5 mg + sitagliptin 100 mg tablet, 28	11561L		Diabetes mellitus type 2
ertugliflozin 5 mg + sitagliptin 100 mg tablet, 28	11579K		Diabetes mellitus type 2
ertugliflozin 5 mg tablet, 28	11577H		Diabetes mellitus type 2
ertugliflozin 5 mg tablet, 28	11585R		Diabetes mellitus type 2
ertugliflozin 7.5 mg + metformin hydrochloride 1 g tablet, 56	11563N		Diabetes mellitus type 2
ertugliflozin 7.5 mg + metformin hydrochloride 1 g tablet, 56	11569X		Diabetes mellitus type 2
ertugliflozin 7.5 mg + metformin hydrochloride 500 mg tablet, 56	11562M		Diabetes mellitus type 2

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
ertugliflozin 7.5 mg + metformin hydrochloride 500 mg tablet, 56	11568W		Diabetes mellitus type 2
esomeprazole 20 mg enteric capsule, 30	10343J		M - Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion, Scleroderma oesophagus
esomeprazole 20 mg enteric capsule, 30	11687D		Gastro-oesophageal reflux disease
esomeprazole 20 mg enteric capsule, 30	12275C		Complex gastro-oesophageal reflux disease (GORD)
esomeprazole 20 mg enteric tablet, 30	11692J		Gastro-oesophageal reflux disease
esomeprazole 20 mg enteric tablet, 30	12287Q		Complex gastro-oesophageal reflux disease (GORD)
esomeprazole 40 mg enteric capsule, 30	10331R		M - Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion, Scleroderma oesophagus
esomeprazole 40 mg enteric capsule, 30	12290W		Complex gastro-oesophageal reflux disease (GORD)
esomeprazole 40 mg enteric tablet, 30	12283L		Complex gastro-oesophageal reflux disease (GORD)
famotidine 20 mg tablet, 60	2487X		
famotidine 40 mg tablet, 30	2488Y		
glibenclamide 5 mg tablet, 100	2939Q		
gliclazide 30 mg modified release tablet, 100	8535F		
gliclazide 60 mg modified release tablet, 60	9302N		
gliclazide 80 mg tablet, 100	2449X		
glimepiride 1 mg tablet, 30	8450R		
glimepiride 2 mg tablet, 30	8451T		
glimepiride 3 mg tablet, 30	8533D		
glimepiride 4 mg tablet, 30	8452W		
glipizide 5 mg tablet, 100	2440K		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
lansoprazole 15 mg enteric capsule, 30	8198L		M - Gastro-oesophageal reflux disease, Scleroderma oesophagus
lansoprazole 15 mg orally disintegrating tablet, 28	9331D		M - Gastro-oesophageal reflux disease, Scleroderma oesophagus
lansoprazole 30 mg enteric capsule, 28	2241Y		Scleroderma oesophagus
lansoprazole 30 mg enteric capsule, 28	11669E		Gastro-oesophageal reflux disease
lansoprazole 30 mg enteric capsule, 28	12284M		Complex gastro-oesophageal reflux disease (GORD)
lansoprazole 30 mg orally disintegrating tablet, 28	9478W		Scleroderma oesophagus
lansoprazole 30 mg orally disintegrating tablet, 28	11697P		Gastro-oesophageal reflux disease
lansoprazole 30 mg orally disintegrating tablet, 28	12276D		Complex gastro-oesophageal reflux disease (GORD)
linagliptin 2.5 mg + metformin hydrochloride 1 g tablet, 60	10044P		Diabetes mellitus type 2
linagliptin 2.5 mg + metformin hydrochloride 1 g tablet, 60	11282T		Diabetes mellitus type 2
linagliptin 2.5 mg + metformin hydrochloride 500 mg tablet, 60	10038H		Diabetes mellitus type 2
linagliptin 2.5 mg + metformin hydrochloride 500 mg tablet, 60	11274J		Diabetes mellitus type 2
linagliptin 2.5 mg + metformin hydrochloride 850 mg tablet, 60	10045Q		Diabetes mellitus type 2
linagliptin 2.5 mg + metformin hydrochloride 850 mg tablet, 60	11294K		Diabetes mellitus type 2
linagliptin 5 mg tablet, 30	3387G		Diabetes mellitus type 2
linagliptin 5 mg tablet, 30	11280Q		Diabetes mellitus type 2
macrogol-3350 1 g/g powder for oral liquid, 510 g	3416T		M - Chronic constipation, Constipation, Faecal impaction
macrogol-3350 13.125 g + sodium chloride 350.7 mg + sodium bicarbonate 178.5 mg + potassium chloride 46.6 mg powder for oral liquid, 30 sachets	8612G		M - Chronic constipation, Constipation, Faecal impaction

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
macrogol-3350 13.125 g/25 mL + sodium chloride 350.7 mg/25 mL + sodium bicarbonate 178.5 mg/25 mL + potassium chloride 46.6 mg/25 mL oral liquid, 500 mL	10126Y		M - Chronic constipation, Constipation, Faecal impaction
mesalazine 1 g modified release granules, 120 sachets	2234N		M - Crohn disease, Ulcerative colitis
mesalazine 1 g enteric tablet, 60	11554D		M - Crohn disease, Ulcerative colitis
mesalazine 1 g modified release granules, 100 sachets	8599N		Ulcerative colitis
mesalazine 1 g modified release granules, 100 sachets	12203G		M - Crohn disease, Ulcerative colitis
mesalazine 1 g modified release tablet, 60	3413P		M - Crohn disease, Ulcerative colitis
mesalazine 1.2 g modified release tablet, 60	9353G		Ulcerative colitis
mesalazine 1.5 g modified release granules, 60 sachets	9206M		Ulcerative colitis
mesalazine 1.6 g enteric tablet, 60	12463Y		Ulcerative colitis
mesalazine 2 g modified release granules, 60 sachets	2287J		M - Crohn disease, Ulcerative colitis
mesalazine 250 mg enteric tablet, 100	1611T		M - Crohn disease, Ulcerative colitis
mesalazine 3 g modified release granules, 30 sachets	10257W		Ulcerative colitis
mesalazine 4 g modified release granules, 30 sachets	10254Q		Ulcerative colitis
mesalazine 500 mg enteric tablet, 100	8731M		M - Crohn disease, Ulcerative colitis
mesalazine 500 mg modified release granules, 100 sachets	8598M		Ulcerative colitis
mesalazine 500 mg modified release tablet, 100	2214M		M - Crohn disease, Ulcerative colitis
mesalazine 800 mg enteric tablet, 90	11210B		Ulcerative colitis
metformin hydrochloride 1 g modified release tablet, 60	3439B		
metformin hydrochloride 1 g tablet, 90	8607B		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
metformin hydrochloride 500 mg modified release tablet, 120	9435N		
metformin hydrochloride 500 mg tablet, 100	2430X		
metformin hydrochloride 850 mg tablet, 60	1801T		
nizatidine 150 mg capsule, 60	1505F		
nizatidine 300 mg capsule, 30	1504E		
olsalazine sodium 250 mg capsule, 100	1728Y		Ulcerative colitis
olsalazine sodium 500 mg tablet, 100	8086N		Ulcerative colitis
omeprazole 10 mg enteric tablet, 30	8332M		M - Gastro-oesophageal reflux disease, Scleroderma oesophagus, Zollinger-Ellison syndrome
omeprazole 20 mg enteric capsule, 30	1327W		M - Scleroderma oesophagus, Zollinger-Ellison syndrome
omeprazole 20 mg enteric capsule, 30	11682W		Gastro-oesophageal reflux disease
omeprazole 20 mg enteric capsule, 30	12281J		Complex gastro-oesophageal reflux disease (GORD)
omeprazole 20 mg enteric tablet, 30	8333N		M - Scleroderma oesophagus, Zollinger-Ellison syndrome
omeprazole 20 mg enteric tablet, 30	9110L		M - Scleroderma oesophagus, Zollinger-Ellison syndrome
omeprazole 20 mg enteric tablet, 30	11677N		Gastro-oesophageal reflux disease
omeprazole 20 mg enteric tablet, 30	11683X		Gastro-oesophageal reflux disease
omeprazole 20 mg enteric tablet, 30	12270T		Complex gastro-oesophageal reflux disease (GORD)
omeprazole 20 mg enteric tablet, 30	12272X		Complex gastro-oesophageal reflux disease (GORD)
pantoprazole 20 mg enteric tablet, 30	8399C		M - Gastro-oesophageal reflux disease, Scleroderma oesophagus, Zollinger-Ellison syndrome
pantoprazole 40 mg enteric coated granules, 30 sachets	9424B		M - Scleroderma oesophagus, Zollinger-Ellison syndrome

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
pantoprazole 40 mg enteric coated granules, 30 sachets	11678P		Gastro-oesophageal reflux disease
pantoprazole 40 mg enteric coated granules, 30 sachets	12282K		Complex gastro-oesophageal reflux disease (GORD)
pantoprazole 40 mg enteric tablet, 30	8008L		M - Scleroderma oesophagus, Zollinger-Ellison syndrome
pantoprazole 40 mg enteric tablet, 30	11681T		Gastro-oesophageal reflux disease
pantoprazole 40 mg enteric tablet, 30	12277E		Complex gastro-oesophageal reflux disease (GORD)
pioglitazone 15 mg tablet, 28	8694N		Diabetes mellitus type 2
pioglitazone 30 mg tablet, 28	8695P		Diabetes mellitus type 2
pioglitazone 45 mg tablet, 28	8696Q		Diabetes mellitus type 2
potassium chloride 595 mg + potassium bicarbonate 384 mg + potassium carbonate 152 mg (total potassium 14 mmol) effervescent tablet, 60	3012M		
potassium chloride 600 mg (potassium 8 mmol) modified release tablet, 200	1841X		
rabeprazole sodium 10 mg enteric tablet, 28	8507R		M - Gastro-oesophageal reflux disease, Scleroderma oesophagus
rabeprazole sodium 20 mg enteric tablet, 30	8508T		Scleroderma oesophagus
rabeprazole sodium 20 mg enteric tablet, 30	11670F		Gastro-oesophageal reflux disease
rabeprazole sodium 20 mg enteric tablet, 30	12286P		Complex gastro-oesophageal reflux disease (GORD)
ranitidine 150 mg tablet, 60	1978D		
ranitidine 150 mg/10 mL oral liquid, 300 mL	8162N		
ranitidine 300 mg tablet, 30	1977C		
rhamnus frangula 80 mg/g + sterculia 620 mg/g granules, 500 g	1104D		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
saxagliptin 2.5 mg + metformin hydrochloride 1 g modified release tablet, 56	10048W		Diabetes mellitus type 2

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
saxagliptin 2.5 mg + metformin hydrochloride 1 g modified release tablet, 56	11285Y		Diabetes mellitus type 2
saxagliptin 2.5 mg tablet, 28	10128C		Diabetes mellitus type 2
saxagliptin 2.5 mg tablet, 28	11292H		Diabetes mellitus type 2
saxagliptin 5 mg + dapagliflozin 10 mg tablet, 28	11286B		Diabetes mellitus type 2
saxagliptin 5 mg + dapagliflozin 10 mg tablet, 28	11305B		Diabetes mellitus type 2
saxagliptin 5 mg + metformin hydrochloride 1 g modified release tablet, 28	10051B		Diabetes mellitus type 2
saxagliptin 5 mg + metformin hydrochloride 1 g modified release tablet, 28	11299Q		Diabetes mellitus type 2
saxagliptin 5 mg + metformin hydrochloride 500 mg modified release tablet, 28	10055F		Diabetes mellitus type 2
saxagliptin 5 mg + metformin hydrochloride 500 mg modified release tablet, 28	11312J		Diabetes mellitus type 2
saxagliptin 5 mg tablet, 28	8983T		Diabetes mellitus type 2
saxagliptin 5 mg tablet, 28	11311H		Diabetes mellitus type 2
semaglutide 1.34 mg/mL injection, 1 x 1.5 mL pen device	12080T		Diabetes mellitus type 2
semaglutide 1.34 mg/mL injection, 1 x 3 mL pen device	12075M		Diabetes mellitus type 2
sitagliptin 100 mg + metformin hydrochloride 1 g modified release tablet, 28	10089B		Diabetes mellitus type 2
sitagliptin 100 mg + metformin hydrochloride 1 g modified release tablet, 28	11566R		Diabetes mellitus type 2
sitagliptin 100 mg tablet, 28	9182G		Diabetes mellitus type 2
sitagliptin 100 mg tablet, 28	11576G		Diabetes mellitus type 2
sitagliptin 25 mg tablet, 28	9180E		Diabetes mellitus type 2
sitagliptin 25 mg tablet, 28	11572C		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 1 g modified release tablet, 56	10090C		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 1 g modified release tablet, 56	11580L		Diabetes mellitus type 2

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
sitagliptin 50 mg + metformin hydrochloride 1 g tablet, 56	9451K		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 1 g tablet, 56	11574E		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 500 mg tablet, 56	9449H		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 500 mg tablet, 56	11586T		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 850 mg tablet, 56	9450J		Diabetes mellitus type 2
sitagliptin 50 mg + metformin hydrochloride 850 mg tablet, 56	11582N		Diabetes mellitus type 2
sitagliptin 50 mg tablet, 28	9181F		Diabetes mellitus type 2
sitagliptin 50 mg tablet, 28	11573D		Diabetes mellitus type 2
sodium citrate dihydrate 450 mg/5 mL + lauryl sulfoacetate sodium 45 mg/5 mL + sorbitol 3.125 g/5 mL enema, 12 x 5 mL	2091C		M - Anorectal congenital abnormalities, Constipation, Megacolon, Terminal malignant neoplasia
thiamine hydrochloride 100 mg tablet, 100	1070H		Thiamine deficiency
vildagliptin 50 mg + metformin hydrochloride 1 g tablet, 60	5476F		Diabetes mellitus type 2
vildagliptin 50 mg + metformin hydrochloride 500 mg tablet, 60	5474D		Diabetes mellitus type 2
vildagliptin 50 mg + metformin hydrochloride 850 mg tablet, 60	5475E		Diabetes mellitus type 2
vildagliptin 50 mg tablet, 60	3415R		Diabetes mellitus type 2

1.2 BLOOD

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
apixaban 2.5 mg tablet, 60	2744K		M - Prevention of recurrent venous thromboembolism, Prevention of stroke or systemic embolism
apixaban 5 mg tablet, 60	2735Y		M - Deep vein thrombosis, Prevention of stroke or systemic embolism, Pulmonary embolism
clopidogrel 75 mg + aspirin 100 mg tablet, 30	9296G		
clopidogrel 75 mg tablet, 28	2275R		M- Acute coronary syndrome MI or unstable angina, cardiac stent insertion
clopidogrel 75 mg tablet, 28	9317J		M- Acute coronary syndrome MI or unstable angina, cardiac stent insertion
clopidogrel 75 mg tablet, 28	8358X		
clopidogrel 75 mg tablet, 28	9354H		
dabigatran etexilate 110 mg capsule, 60	2753X		Prevention of stroke or systemic embolism
dabigatran etexilate 150 mg capsule, 60	2769R		Prevention of stroke or systemic embolism
rivaroxaban 15 mg tablet, 28	2691P		Prevention of stroke or systemic embolism
rivaroxaban 2.5 mg tablet, 60	12192Q		Chronic stable atherosclerotic disease
rivaroxaban 2.5 mg tablet, 60	12197Y		Chronic stable atherosclerotic disease
rivaroxaban 20 mg tablet, 28	2268J		M - Deep vein thrombosis, Prevention of recurrent venous thromboembolism, Prevention of stroke or systemic embolism, Pulmonary embolism
ticagrelor 90 mg tablet, 56	1418P		Acute coronary syndrome (myocardial infarction or unstable angina)

1.3 CARDIOVASCULAR SYSTEM

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
amiloride hydrochloride dihydrate 5 mg + hydrochlorothiazide 50 mg tablet, 50	1486F		
amlodipine 10 mg + atorvastatin 10 mg tablet, 30	9053L		
amlodipine 10 mg + atorvastatin 20 mg tablet, 30	9054M		
amlodipine 10 mg + atorvastatin 40 mg tablet, 30	9055N		
amlodipine 10 mg + atorvastatin 80 mg tablet, 30	9056P		
amlodipine 10 mg + valsartan 160 mg + hydrochlorothiazide 12.5 mg tablet, 28	5287G		Hypertension
amlodipine 10 mg + valsartan 160 mg + hydrochlorothiazide 25 mg tablet, 28	5288H		Hypertension
amlodipine 10 mg + valsartan 160 mg tablet, 28	9377M		Hypertension
amlodipine 10 mg + valsartan 320 mg + hydrochlorothiazide 25 mg tablet, 28	5289J		Hypertension
amlodipine 10 mg + valsartan 320 mg tablet, 28	5460J		Hypertension
amlodipine 10 mg tablet, 30	2752W		
amlodipine 5 mg + atorvastatin 10 mg tablet, 30	9049G		
amlodipine 5 mg + atorvastatin 20 mg tablet, 30	9050H		
amlodipine 5 mg + atorvastatin 40 mg tablet, 30	9051J		
amlodipine 5 mg + atorvastatin 80 mg tablet, 30	9052K		
amlodipine 5 mg + valsartan 160 mg + hydrochlorothiazide 12.5 mg tablet, 28	5285E		Hypertension
amlodipine 5 mg + valsartan 160 mg + hydrochlorothiazide 25 mg tablet, 28	5286F		Hypertension
amlodipine 5 mg + valsartan 160 mg tablet, 28	9376L		Hypertension
amlodipine 5 mg + valsartan 320 mg tablet, 28	5459H		Hypertension
amlodipine 5 mg + valsartan 80 mg tablet, 28	9375K		Hypertension
amlodipine 5 mg tablet, 30	2751T		
atenolol 50 mg tablet, 30	1081X		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
atenolol 50 mg/10 mL oral liquid, 300 mL	2243C		For a patient who is unable to take a solid dose form of atenolol.
bisoprolol fumarate 10 mg tablet, 28	8606Y		Moderate to severe heart failure
bisoprolol fumarate 2.5 mg tablet, 28	8604W		Moderate to severe heart failure
bisoprolol fumarate 5 mg tablet, 28	8605X		Moderate to severe heart failure
candesartan cilexetil 16 mg + hydrochlorothiazide 12.5 mg tablet, 30	8504N		Hypertension
candesartan cilexetil 16 mg tablet, 30	8297Q		
candesartan cilexetil 32 mg + hydrochlorothiazide 12.5 mg tablet, 30	9314F		Hypertension
candesartan cilexetil 32 mg + hydrochlorothiazide 25 mg tablet, 30	9315G		Hypertension
candesartan cilexetil 32 mg tablet, 30	8889W		
candesartan cilexetil 4 mg tablet, 30	8295N		
candesartan cilexetil 8 mg tablet, 30	8296P		
captopril 5 mg/mL oral liquid, 95 mL	8760C		Patients unable to take a solid dose form of an ACE inhibitor.
carvedilol 12.5 mg tablet, 60	8257N		M - Moderate to severe heart failure
carvedilol 25 mg tablet, 60	8258P		M - Moderate to severe heart failure
carvedilol 6.25 mg tablet, 60	8256M		M - Moderate to severe heart failure
chlortalidone 25 mg tablet, 50	1585K		
clonidine hydrochloride 100 microgram tablet, 100	3145M		
clonidine hydrochloride 150 microgram tablet, 100	3141H		
diltiazem hydrochloride 180 mg modified release capsule, 30	1312C		
diltiazem hydrochloride 240 mg modified release capsule, 30	1313D		
diltiazem hydrochloride 360 mg modified release capsule, 30	8480H		
diltiazem hydrochloride 60 mg tablet, 90	1335G		

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
enalapril maleate 10 mg tablet, 30	1368B		
enalapril maleate 20 mg + hydrochlorothiazide 6 mg tablet, 30	8477E		Hypertension
enalapril maleate 20 mg tablet, 30	1369C		
enalapril maleate 5 mg tablet, 30	1370D		
eplerenone 25 mg tablet, 30	8879H		Heart failure with a left ventricular ejection fraction of 40% or less
eplerenone 50 mg tablet, 30	8880J		Heart failure with a left ventricular ejection fraction of 40% or less
eprosartan 400 mg tablet, 28	8397Y		
eprosartan 400 mg tablet, 28	8951D		
eprosartan 600 mg + hydrochlorothiazide 12.5 mg tablet, 28	8624X		Hypertension
eprosartan 600 mg tablet, 28	5491B		
eprosartan 600 mg tablet, 28	8447N		
ezetimibe 10 mg + atorvastatin 10 mg tablet, 30	10392Y		Hypercholesterolaemia
ezetimibe 10 mg + atorvastatin 20 mg tablet, 30	10393B		Hypercholesterolaemia
ezetimibe 10 mg + atorvastatin 40 mg tablet, 30	10377E		Hypercholesterolaemia
ezetimibe 10 mg + atorvastatin 80 mg tablet, 30	10376D		Hypercholesterolaemia
ezetimibe 10 mg + simvastatin 10 mg tablet, 30	9483D		Hypercholesterolaemia
ezetimibe 10 mg + simvastatin 20 mg tablet, 30	9484E		Hypercholesterolaemia
ezetimibe 10 mg + simvastatin 40 mg tablet, 30	8881K		Hypercholesterolaemia
ezetimibe 10 mg + simvastatin 80 mg tablet, 30	8882L		Hypercholesterolaemia
ezetimibe 10 mg tablet [30] (&) rosuvastatin 10 mg tablet [30], 60	10208G		Hypercholesterolaemia
ezetimibe 10 mg tablet [30] (&) rosuvastatin 20 mg tablet [30], 60	10201X		Hypercholesterolaemia
ezetimibe 10 mg tablet [30] (&) rosuvastatin 40 mg tablet [30], 60	10207F		Hypercholesterolaemia
ezetimibe 10 mg tablet [30] (&) rosuvastatin 5 mg tablet [30], 60	10204C		Hypercholesterolaemia

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
ezetimibe 10 mg tablet, 30	8757X		Hypercholesterolaemia
felodipine 10 mg modified release tablet, 30	2367N		
felodipine 2.5 mg modified release tablet, 30	2361G		
felodipine 5 mg modified release tablet, 30	2366M		
fosinopril sodium 10 mg tablet, 30	1182F		
fosinopril sodium 20 mg + hydrochlorothiazide 12.5 mg tablet, 30	8401E		Hypertension
fosinopril sodium 20 mg tablet, 30	1183G		
furosemide (frusemide) 10 mg/mL oral liquid, 30 mL	2411X		
furosemide (frusemide) 20 mg tablet, 100	2414C		
furosemide (frusemide) 20 mg tablet, 50	1810G		
furosemide (frusemide) 40 mg tablet, 100	2412Y		
furosemide (frusemide) 500 mg tablet, 50	2415D		
glyceryl trinitrate 600 microgram sublingual tablet, 100	1459J		
glyceryl trinitrate 300 microgram sublingual tablet,	11027J		
glyceryl trinitrate 10 mg/24 hours patch, 30	8011P		
glyceryl trinitrate 10 mg/24 hours patch, 30	1516T		
glyceryl trinitrate 10 mg/24 hours patch, 30	8028M		
glyceryl trinitrate 15mg/24 hours patch, 30	8026K		
glyceryl trinitrate 15mg/24 hours patch, 30	8119H		
glyceryl trinitrate 400 microgram/actuation spray, 200 actuations	8171C		
glyceryl trinitrate 5 mg/24 hours patch, 30	8010N		
glyceryl trinitrate 5 mg/24 hours patch, 30	1515R		
glyceryl trinitrate 5 mg/24 hours patch, 30	8027L		
hydralazine hydrochloride 25 mg tablet, 100	1640H		
hydralazine hydrochloride 50 mg tablet, 100	1639G		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
hydrochlorothiazide 25 mg tablet, 100	1484D		
indapamide hemihydrate 1.5 mg modified release tablet, 90	8532C		
indapamide hemihydrate 2.5 mg tablet, 90	2436F		
irbesartan 150 mg + hydrochlorothiazide 12.5 mg tablet, 30	8404H		Hypertension
irbesartan 150 mg tablet, 30	8247C		
irbesartan 300 mg + hydrochlorothiazide 12.5 mg tablet, 30	8405J		Hypertension
irbesartan 300 mg + hydrochlorothiazide 25 mg tablet, 30	2136K		Hypertension
irbesartan 300 mg tablet, 30	8248D		
irbesartan 75 mg tablet, 30	8246B		
isosorbide dinitrate 5 mg sublingual tablet, 100	2588f		
isosorbide mononitrate 120 mg modified release tablet, 30	8273K		
isosorbide mononitrate 60 mg modified release tablet, 30	1558B		
labetalol hydrochloride 100 mg tablet, 100	1566K		
labetalol hydrochloride 200 mg tablet, 100	1567L		
lercanidipine hydrochloride 10 mg + enalapril maleate 10 mg tablet, 28	9144G		Hypertension
lercanidipine hydrochloride 10 mg + enalapril maleate 20 mg tablet, 28	9145H		Hypertension
lercanidipine hydrochloride 10 mg tablet, 28	8534E		
lercanidipine hydrochloride 20 mg tablet, 28	8679T		
lisinopril 10 mg tablet, 30	2457H		
lisinopril 20 mg tablet, 30	2458J		
lisinopril 5 mg tablet, 30	2456G		
losartan potassium 25 mg tablet, 30	5452Y		
losartan potassium 50 mg tablet, 30	8203R		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
methyldopa 250 mg tablet, 100	1629R		
METOPROLOL SUCCINATE Tablet 190 mg (controlled release), 30	8735R		Moderate to severe heart failure
METOPROLOL SUCCINATE Tablet 47.5 mg (controlled release), 30	8733P		Moderate to severe heart failure
METOPROLOL SUCCINATE Tablet 95 mg (controlled release), 30	8734Q		Moderate to severe heart failure
METOPROLOL TARTRATE Tablet 100 mg, 60	1325R		
METOPROLOL TARTRATE Tablet 50 mg, 100	1324Q		
minoxidil 10 mg tablet, 100	2313R		Severe refractory hypertension
moxonidine 200 microgram tablet, 30	9019Q		Hypertension
moxonidine 400 microgram tablet, 30	9020R		Hypertension
nebivolol 1.25 mg tablet, 28	9316H		Moderate to severe heart failure
nebivolol 10 mg tablet, 28	9312D		Moderate to severe heart failure
nebivolol 5 mg tablet, 28	9311C		Moderate to severe heart failure
nicorandil 10 mg tablet, 60	8228C		
nicorandil 20 mg tablet, 60	8229D		
nifedipine 30 mg modified release tablet, 30	1906H		
nifedipine 60 mg modified release tablet, 30	1907J		
olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet, 30	10005N		Hypertension
olmesartan medoxomil 20 mg + amlodipine 5 mg tablet, 30	5292M		Hypertension
olmesartan medoxomil 20 mg + hydrochlorothiazide 12.5 mg tablet, 30	2161R		Hypertension
olmesartan medoxomil 20 mg tablet, 30	2147B		
olmesartan medoxomil 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg tablet, 30	2836G		Hypertension
olmesartan medoxomil 40 mg + amlodipine 10 mg + hydrochlorothiazide 25 mg tablet, 30	2953K		Hypertension

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
olmesartan medoxomil 40 mg + amlodipine 10 mg tablet, 30	5294P		Hypertension
olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet, 30	2880N		Hypertension
olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 25 mg tablet, 30	2864R		Hypertension
olmesartan medoxomil 40 mg + amlodipine 5 mg tablet, 30	5293N		Hypertension
olmesartan medoxomil 40 mg + hydrochlorothiazide 12.5 mg tablet, 30	2166B		Hypertension
olmesartan medoxomil 40 mg + hydrochlorothiazide 25 mg tablet, 30	2170F		Hypertension
olmesartan medoxomil 40 mg tablet, 30	2148C		
oxprenolol hydrochloride 40 mg tablet, 100	2961W		
perindopril arginine 10 mg + amlodipine 10 mg tablet, 30	9349C		M - Hypertension, Stable coronary heart disease
perindopril arginine 10 mg + amlodipine 5 mg tablet, 30	9348B		M - Hypertension, Stable coronary heart disease
perindopril arginine 10 mg tablet, 30	9008D		
perindopril arginine 2.5 mg + indapamide hemihydrate 625 microgram tablet, 30	2190G		
perindopril arginine 2.5 mg tablet, 30	9006B		
perindopril arginine 5 mg + amlodipine 10 mg tablet, 30	9347Y		M - Hypertension, Stable coronary heart disease
perindopril arginine 5 mg + amlodipine 5 mg tablet, 30	9346X		M - Hypertension, Stable coronary heart disease
perindopril arginine 5 mg + indapamide hemihydrate 1.25 mg tablet, 30	2845R		Hypertension
perindopril arginine 5 mg tablet, 30	9007C		
perindopril erbumine 2 mg tablet, 30	3050M		
perindopril erbumine 4 mg + indapamide hemihydrate 1.25 mg tablet, 30	8449Q		Hypertension
perindopril erbumine 4 mg tablet, 30	3051N		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
perindopril erbumine 8 mg tablet, 30	8704D		
pindolol 5 mg tablet, 100	3062E		
prazosin 1 mg tablet, 100	1479W		
prazosin 2 mg tablet, 100	1480X		
prazosin 5 mg tablet, 100	1478T		
propranolol hydrochloride 10 mg tablet, 100	2565B		
propranolol hydrochloride 160 mg tablet, 50	2899N		
propranolol hydrochloride 40 mg tablet, 100	2566C		
quinapril 10 mg + hydrochlorothiazide 12.5 mg tablet, 30	8589C		Hypertension
quinapril 10 mg tablet, 30	1969P		
quinapril 20 mg + hydrochlorothiazide 12.5 mg tablet, 30	8590D		Hypertension
quinapril 20 mg tablet, 30	1970Q		
quinapril 5 mg tablet, 30	1968N		
ramipril 1.25 mg capsule, 30	9120B		
ramipril 1.25 mg tablet, 30	1944H		
ramipril 10 mg capsule, 30	8470T		
ramipril 10 mg tablet, 30	1316G		
ramipril 2.5 mg + felodipine 2.5 mg modified release tablet, 30	2626F		Hypertension
ramipril 2.5 mg capsule, 30	9121C		
ramipril 2.5 mg tablet, 30	1945J		
ramipril 5 mg + felodipine 5 mg modified release tablet, 30	2629J		Hypertension
ramipril 5 mg capsule, 30	9122D		
ramipril 5 mg tablet, 30	1946K		
sacubitril 24.3 mg + valsartan 25.7 mg tablet, 56	11123K		Chronic heart failure
sacubitril 48.6 mg + valsartan 51.4 mg tablet, 56	11131W		Chronic heart failure

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
sacubitril 97.2 mg + valsartan 102.8 mg tablet, 56	11122J		Chronic heart failure
spironolactone 100 mg tablet, 100	2340E		
spironolactone 25 mg tablet, 100	2339D		
telmisartan 40 mg + amlodipine 10 mg tablet, 28	8979N		Hypertension
telmisartan 40 mg + amlodipine 5 mg tablet, 28	8978M		Hypertension
telmisartan 40 mg + hydrochlorothiazide 12.5 mg tablet, 28	8622T		Hypertension
telmisartan 40 mg tablet, 28	8355R		
telmisartan 80 mg + amlodipine 10 mg tablet, 28	8981Q		Hypertension
telmisartan 80 mg + amlodipine 5 mg tablet, 28	8980P		Hypertension
telmisartan 80 mg + hydrochlorothiazide 12.5 mg tablet, 28	8623W		Hypertension
telmisartan 80 mg + hydrochlorothiazide 25 mg tablet, 28	9381R		Hypertension
telmisartan 80 mg tablet, 28	8356T		
trandolapril 1 mg capsule, 28	2792Y		
trandolapril 2 mg + verapamil hydrochloride 180 mg modified release tablet, 28	9387C		Hypertension
trandolapril 2 mg capsule, 28	2793B		
trandolapril 4 mg + verapamil hydrochloride 240 mg modified release tablet, 28	2857J		Hypertension
trandolapril 4 mg capsule, 28	8758Y		
trandolapril 500 microgram capsule, 28	2791X		
valsartan 160 mg + hydrochlorothiazide 12.5 mg tablet, 28	9373H		Hypertension
valsartan 160 mg + hydrochlorothiazide 25 mg tablet, 28	9374J		Hypertension
valsartan 160 mg tablet, 28	9370E		
valsartan 320 mg + hydrochlorothiazide 12.5 mg tablet, 28	9481B		Hypertension

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
valsartan 320 mg + hydrochlorothiazide 25 mg tablet, 28	9482C		Hypertension
valsartan 320 mg tablet, 28	9371F		
valsartan 80 mg + hydrochlorothiazide 12.5 mg tablet, 28	9372G		Hypertension
valsartan 80 mg tablet, 28	9369D		
verapamil hydrochloride 180 mg modified release tablet, 30	2208F		
verapamil hydrochloride 240 mg modified release tablet, 30	1241H		
verapamil hydrochloride 80 mg tablet, 100	1250T		

1.4 DERMATOLOGICALS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
adapalene 0.1% + benzoyl peroxide 2.5% gel, 30 g	8955H		Severe acne vulgaris
calcipotriol 0.005% + betamethasone (as dipropionate) 0.05% foam, 60 g	11091R		Chronic stable plaque type psoriasis vulgaris
calcipotriol 0.005% + betamethasone (as dipropionate) 0.05% ointment, 30 g	9494Q		Chronic stable plaque type psoriasis vulgaris

1.5 HORMONAL MODULATORS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
bromocriptine 2.5 mg tablet, 30	1443Y		M - Acromegaly, Parkinson disease, Pathological hyperprolactinaemia
cabergoline 500 microgram tablet, 8	8114C		Pathological hyperprolactinaemia
cyproterone acetate 50 mg tablet, 20	1269T		Moderate to severe androgenisation
dutasteride 500 microgram + tamsulosin hydrochloride 400 microgram modified release capsule, 30	5490Y		Benign prostatic hyperplasia
dutasteride 500 microgram capsule, 30	5468T		Benign prostatic hyperplasia
estradiol 0.1% (1 mg/g) gel, 28 x 1 g sachets	8286D		
estradiol 1 mg + dydrogesterone 5 mg tablet, 28	10142T		
estradiol 1 mg tablet [14] (&) estradiol 1 mg + dydrogesterone 10 mg tablet [14], 28	10146B		
estradiol 10 microgram modified release pessary, 18	10203B		
estradiol 100 microgram/24 hours patch, 4	8126Q		
estradiol 100 microgram/24 hours patch, 8	8312L		
estradiol 100 microgram/24 hours patch, 8	8765H		
estradiol 2 mg tablet [14] (&) estradiol 2 mg + dydrogesterone 10 mg tablet [14], 28	8244X		
estradiol 2 mg tablet, 56	8274L		
estradiol 25 microgram/24 hours patch, 4	8485N		
estradiol 25 microgram/24 hours patch, 8	8311K		
estradiol 25 microgram/24 hours patch, 8	8761D		
estradiol 37.5 microgram/24 hours patch, 8	8762E		
estradiol 50 microgram/24 hours + norethisterone acetate 140 microgram/24 hours patch, 8	8427M		
estradiol 50 microgram/24 hours + norethisterone acetate 250 microgram/24 hours patch, 8	8428N		
estradiol 50 microgram/24 hours patch [4] (&) estradiol 50 microgram/24 hours + norethisterone acetate 140 microgram/24 hours patch [4], 8	8425K		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
estradiol 50 microgram/24 hours patch [4] (& estradiol 50 microgram/24 hours + norethisterone acetate 250 microgram/24 hours patch [4], 8	8426L		
estradiol 50 microgram/24 hours patch, 4	8125P		
estradiol 50 microgram/24 hours patch, 8	8140K		
estradiol 50 microgram/24 hours patch, 8	8763F		
estradiol 75 microgram/24 hours patch, 4	8486P		
estradiol 75 microgram/24 hours patch, 8	8764G		
estradiol valerate 1 mg tablet, 56	1663M		
estradiol valerate 2 mg tablet, 56	1664N		
estriol 0.1% (1 mg/g) cream, 15 g	1781R		
estriol 500 microgram pessary, 15	1771F		
medroxyprogesterone acetate 10 mg tablet, 100	2722G		Endometriosis
medroxyprogesterone acetate 10 mg tablet, 30	2321E		
medroxyprogesterone acetate 5 mg tablet, 56	2323G		
norethisterone 5 mg tablet, 30	2993M		
oxybutynin 3.9 mg/24 hours patch, 8	9454N		Detrusor overactivity
oxybutynin hydrochloride 5 mg tablet, 100	8039D		Detrusor overactivity
oxybutynin hydrochloride 5 mg tablet, 100	13098J		Detrusor overactivity
propantheline bromide 15 mg tablet, 100	1953T		Detrusor overactivity
quinagolide 75 microgram tablet, 30	8822H		Pathological hyperprolactinaemia
sodium bicarbonate 840 mg capsule, 100	9470K		
testosterone 1% (12.5 mg/actuation) gel, 2 x 60 actuations	10380H		M - Androgen deficiency, Constitutional delay of growth or puberty, Micropenis, Pubertal induction
testosterone 1% (50 mg/5 g) gel, 30 x 5 g sachets	8830R		M - Androgen deficiency, Constitutional delay of growth or puberty, Micropenis, Pubertal induction

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
testosterone 2% (23 mg/actuation) gel, 56 actuations	11740X		M - Androgen deficiency, Constitutional delay of growth or puberty, Micropenis, Pubertal induction
testosterone 5 mg/24 hours patch, 30	8619P		M - Androgen deficiency, Constitutional delay of growth or puberty, Micropenis, Pubertal induction
testosterone 5% (50 mg/mL) cream, 50 mL	10378F		M - Androgen deficiency, Constitutional delay of growth or puberty, Micropenis, Pubertal induction

1.6 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
calcitonin salmon (salcatonin) 100 units/mL injection, 5 x 1 mL ampoules	2997R		M - Hypercalcaemia, Symptomatic Paget disease of bone
carbimazole 5 mg tablet, 100	1153Q		
cinacalcet 30 mg tablet, 28	9157Y		Secondary hyperparathyroidism
cinacalcet 60 mg tablet, 28	9158B		Secondary hyperparathyroidism
cinacalcet 90 mg tablet, 28	9159C		Secondary hyperparathyroidism
cortisone acetate 25 mg tablet, 60	1247P		
cortisone acetate 5 mg tablet, 50	1246N		
desmopressin 120 microgram sublingual wafer, 30	9398P		Primary nocturnal enuresis
desmopressin 240 microgram sublingual wafer, 30	8975J		Primary nocturnal enuresis
desmopressin acetate 10 microgram/actuation nasal spray, 50 actuations	12458Q		Cranial diabetes insipidus
desmopressin acetate 10 microgram/actuation nasal spray, 50 actuations	12459R		Primary nocturnal enuresis
desmopressin acetate 10 microgram/actuation nasal spray, 60 actuations	8711L		Cranial diabetes insipidus
desmopressin acetate 10 microgram/actuation nasal spray, 60 actuations	8712M		Primary nocturnal enuresis
desmopressin acetate 200 microgram tablet, 30	8662X		Cranial diabetes insipidus
desmopressin acetate 200 microgram tablet, 30	8663Y		Primary nocturnal enuresis
dexamethasone 500 microgram tablet, 30	1292B		
hydrocortisone 20 mg tablet, 60	1500Y		
hydrocortisone 4 mg tablet, 50	1499X		
liothyronine sodium 20 microgram tablet, 100	2318B		M - Hypothyroidism, Thyroid cancer
nafarelin 200 microgram/actuation nasal spray, 60 actuations	2962X		Endometriosis
prednisolone (as sodium phosphate) 5 mg/mL oral liquid, 30 mL	8285C		
prednisolone 1 mg tablet, 100	3152X		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
prednisolone 5 mg tablet, 60	1917X		
prednisone 1 mg tablet, 100	1934T		
prednisone 5 mg tablet, 60	1935W		
propylthiouracil 50 mg tablet, 100	1955X		
teriparatide 250 microgram/mL injection, 2.4 mL cartridge	12670W		Severe established osteoporosis

1.7 ANTIINFECTIVES FOR SYSTEMIC USE

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
doxycycline 100 mg modified release capsule, 7	10777F		Severe acne
doxycycline 100 mg tablet, 7	10779H		Severe acne
doxycycline 100 mg tablet, 7	10781K		Severe acne
doxycycline 50 mg modified release capsule, 25	2707L		M - Bronchiectasis, Chronic bronchitis, Severe acne
doxycycline 50 mg tablet, 25	2711Q		M - Bronchiectasis, Chronic bronchitis, Severe acne
doxycycline 50 mg tablet, 25	9106G		M - Bronchiectasis, Chronic bronchitis, Severe acne
erythromycin 250 mg enteric capsule, 25	10780J		Severe acne
methenamine hippurate 1 g tablet, 100	3124K		
minocycline 50 mg tablet, 60	1616C		Severe acne
phenoxymethylpenicillin 250 mg capsule, 50	1705R		Recurrent streptococcal infections (including rheumatic fever)
phenoxymethylpenicillin 250 mg tablet, 25	1703P		Recurrent streptococcal infections (including rheumatic fever)
tobramycin 28 mg powder for inhalation, 224 capsules	10074F		Proven Pseudomonas aeruginosa infection
tobramycin 300 mg/5 mL inhalation solution, 56 x 5 mL ampoules	5442K		Proven Pseudomonas aeruginosa infection

1.8 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
anastrozole 1 mg tablet, 30	8179L		Breast cancer
ciclosporin 10 mg capsule, 60	8657P		
ciclosporin 100 mg capsule, 30	8660T		
ciclosporin 100 mg/mL oral liquid, 50 mL	8661W		
ciclosporin 25 mg capsule, 30	8658Q		
ciclosporin 50 mg capsule, 30	8659R		
cyproterone acetate 100 mg tablet, 50	8019C		
cyproterone acetate 50 mg tablet, 50	1270W		
everolimus 1 mg tablet, 60	9352F		
everolimus 750 microgram tablet, 60	8842J		
exemestane 25 mg tablet, 30	8506Q		Breast cancer
exemestane 25 mg tablet, 30	10103R		Metastatic (Stage IV) breast cancer
leflunomide 10 mg tablet, 30	5449T		Severe active psoriatic arthritis
leflunomide 10 mg tablet, 30	8374R		Severe active rheumatoid arthritis
leflunomide 20 mg tablet, 30	5450W		Severe active psoriatic arthritis
leflunomide 20 mg tablet, 30	8375T		Severe active rheumatoid arthritis
letrozole 2.5 mg tablet, 30	8245Y		Breast cancer
medroxyprogesterone acetate 100 mg tablet, 100	2725K		M - Breast cancer, Endometrial cancer
medroxyprogesterone acetate 200 mg tablet, 60	2316X		M - Breast cancer, Endometrial cancer
medroxyprogesterone acetate 250 mg tablet, 60	2727M		M - Breast cancer, Endometrial cancer
medroxyprogesterone acetate 500 mg tablet, 30	2728N		Advanced breast cancer
methotrexate 50 mg/2 mL injection, 2 mL vial	1818Q		
methotrexate 50 mg/2 mL injection, 5 x 2 mL vials	2395C		
mycophenolate 180 mg enteric tablet, 120	2150E		
mycophenolate 360 mg enteric tablet, 120	2193K		
mycophenolate mofetil 1 g/5 mL powder for oral liquid, 165 mL	8651H		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
mycophenolate mofetil 250 mg capsule, 100	8649F		
mycophenolate mofetil 250 mg capsule, 50	1836P		
mycophenolate mofetil 500 mg tablet, 50	8650G		
sirolimus 1 mg tablet, 100	8724E		
sirolimus 1 mg/mL oral liquid, 60 mL	8725F		
sirolimus 2 mg tablet, 100	8833X		
sirolimus 500 microgram tablet, 100	8984W		
tacrolimus 1 mg capsule, 100	8647D		
tacrolimus 1 mg modified release capsule, 60	5300Y		
tacrolimus 2 mg capsule, 100	10871E		
tacrolimus 3 mg modified release capsule, 50	11914C		
tacrolimus 5 mg capsule, 50	8648E		
tacrolimus 5 mg modified release capsule, 30	5451X		
tacrolimus 500 microgram capsule, 100	8646C		
tacrolimus 500 microgram modified release capsule, 30	5299X		
tacrolimus 750 microgram capsule, 100	10870D		
tamoxifen 20 mg tablet, 30	1880Y		Breast cancer
tamoxifen 20 mg tablet, 30	10911G		Reduction of breast cancer risk
tamoxifen 20 mg tablet, 60	2110C		Breast cancer
toremifene 60 mg tablet, 30	8216K		

1.9 MUSCULO-SKELETAL SYSTEM

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
alendronate 70 mg + colecalciferol 140 microgram (5600 units) tablet, 4	9183H		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
alendronate 70 mg + colecalciferol 70 microgram (2800 units) tablet, 4	9012H		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
alendronate 70 mg tablet, 4	8511Y		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
allopurinol 100 mg tablet, 200	2600W		
allopurinol 300 mg tablet, 60	2604C		
auranofin 3 mg capsule, 60	2022K		
auranofin 3 mg tablet, 60	1095P		
baclofen 10 mg tablet, 100	2729P		
baclofen 25 mg tablet, 100	2730Q		
febuxostat 80 mg tablet, 28	10445R		Chronic gout
penicillamine 125 mg tablet, 100	2721F		
penicillamine 250 mg tablet, 100	2838J		
probenecid 500 mg tablet, 100	1940D		
raloxifene hydrochloride 60 mg tablet, 28	8363E		Established post-menopausal osteoporosis
risedronate sodium 150 mg tablet, 1	9391G		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
risedronate sodium 35 mg enteric tablet, 4	8972F		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
risedronate sodium 35 mg tablet [4] (&) calcium (as carbonate) 500 mg tablet [24], 28	8899J		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
risedronate sodium 35 mg tablet, 4	8621R		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis
risedronate sodium 5 mg tablet, 28	8481J		M - Corticosteroid-induced osteoporosis, Established osteoporosis, Osteoporosis

1.10 NERVOUS SYSTEM

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
amantadine hydrochloride 100 mg capsule, 100	3016R		Parkinson disease
apomorphine hydrochloride hemihydrate 100 mg/20 mL injection, 5 x 20 mL vials	12142C		Parkinson disease
apomorphine hydrochloride hemihydrate 20 mg/2 mL injection, 5 x 2 mL ampoules	12320K		Parkinson disease
apomorphine hydrochloride hemihydrate 30 mg/3 mL injection, 5 x 3 mL cartridges	12133N		Parkinson disease
apomorphine hydrochloride hemihydrate 30 mg/3 mL injection, 5 x 3 mL pen devices	12137T		Parkinson disease
apomorphine hydrochloride hemihydrate 50 mg/10 mL injection, 5 x 10 mL syringes	12319J		Parkinson disease
cabergoline 1 mg tablet, 30	8393R		Parkinson disease
cabergoline 2 mg tablet, 30	8394T		Parkinson disease
carbamazepine 100 mg tablet, 100	2422L		
carbamazepine 100 mg/5 mL oral liquid, 300 mL	2427R		
carbamazepine 200 mg modified release tablet, 200	2426Q		
carbamazepine 200 mg tablet, 100	1706T		
carbamazepine 400 mg modified release tablet, 200	2431Y		
citalopram 10 mg tablet, 28	8702B		Major depressive disorders
citalopram 20 mg tablet, 28	8220P		Major depressive disorders
citalopram 40 mg tablet, 28	8703C		Major depressive disorders
desvenlafaxine 100 mg modified release tablet, 28	9367B		Major depressive disorders
desvenlafaxine 100 mg modified release tablet, 28	10231L		Major depressive disorders
desvenlafaxine 100 mg modified release tablet, 28	10245F		Major depressive disorders
desvenlafaxine 50 mg modified release tablet, 28	9366Y		Major depressive disorders
desvenlafaxine 50 mg modified release tablet, 28	10234P		Major depressive disorders

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
desvenlafaxine 50 mg modified release tablet, 28	10241B		Major depressive disorders
duloxetine 60 mg enteric capsule, 28	9156X		Major depressive disorders
entacapone 200 mg tablet, 100	8367J		Parkinson disease
escitalopram 10 mg tablet, 28	8700X		Major depressive disorders
escitalopram 10 mg tablet, 28	9432K		M - Moderate to severe generalised anxiety disorder (GAD), Moderate to severe social anxiety disorder (social phobia, SAD)
escitalopram 20 mg tablet, 28	8701Y		Major depressive disorders
escitalopram 20 mg tablet, 28	9433L		M - Moderate to severe generalised anxiety disorder (GAD), Moderate to severe social anxiety disorder (social phobia, SAD)
escitalopram 20 mg/mL oral liquid, 15 mL	10181W		M - Major depressive disorders, Moderate to severe generalised anxiety disorder (GAD), Moderate to severe social anxiety disorder (social phobia, SAD)
ethosuximide 250 mg capsule, 200	1413J		
ethosuximide 250 mg capsule, 56	13127X		
ethosuximide 250 mg/5 mL oral liquid, 200 mL	1414K		
fluoxetine 20 mg capsule, 28	1434L		M - Major depressive disorders, Obsessive-compulsive disorder
fluoxetine 20 mg tablet, 28	8270G		M - Major depressive disorders, Obsessive-compulsive disorder
fluvoxamine maleate 100 mg tablet, 30	8174F		M - Major depressive disorders, Obsessive-compulsive disorder
fluvoxamine maleate 50 mg tablet, 30	8512B		M - Major depressive disorders, Obsessive-compulsive disorder
lacosamide 10 mg/mL oral liquid, 200 mL	11694L		Intractable partial epileptic seizures
lacosamide 10 mg/mL oral liquid, 200 mL	12628P		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
lacosamide 100 mg tablet, 56	9335H		Intractable partial epileptic seizures

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
lacosamide 100 mg tablet, 56	12634Y		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
lacosamide 150 mg tablet, 56	9337K		Intractable partial epileptic seizures
lacosamide 150 mg tablet, 56	12627N		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
lacosamide 200 mg tablet, 56	9338L		Intractable partial epileptic seizures
lacosamide 200 mg tablet, 56	12658F		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
lacosamide 50 mg tablet, 14	10293R		Intractable partial epileptic seizures
lacosamide 50 mg tablet, 14	12626M		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
lamotrigine 100 mg tablet, 56	2850B		Epileptic seizures
lamotrigine 200 mg tablet, 56	2851C		Epileptic seizures
lamotrigine 25 mg tablet, 56	2848X		Epileptic seizures
lamotrigine 5 mg tablet, 56	8063J		Epileptic seizures
lamotrigine 50 mg tablet, 56	2849Y		Epileptic seizures
levetiracetam 1 g tablet, 60	8656N		Partial epileptic seizures
levetiracetam 100 mg/mL oral liquid, 300 mL	9169N		Partial epileptic seizures
levetiracetam 250 mg tablet, 60	8654L		Partial epileptic seizures
levetiracetam 500 mg tablet, 60	8655M		Partial epileptic seizures
levodopa 100 mg + benserazide 25 mg capsule, 100	2225D		
levodopa 100 mg + benserazide 25 mg dispersible tablet, 100	8219N		
levodopa 100 mg + benserazide 25 mg modified release capsule, 100	2231K		
levodopa 100 mg + benserazide 25 mg tablet, 100	2229H		
levodopa 100 mg + carbidopa 25 mg + entacapone 200 mg tablet, 100	8798C		Parkinson disease
levodopa 100 mg + carbidopa 25 mg tablet, 100	1242J		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
levodopa 125 mg + carbidopa 31.25 mg + entacapone 200 mg tablet, 100	9345W		Parkinson disease
levodopa 150 mg + carbidopa 37.5 mg + entacapone 200 mg tablet, 100	8799D		Parkinson disease
levodopa 20 mg/mL + carbidopa monohydrate 5 mg/mL intestinal gel, 7 x 100 mL	8970D		Advanced Parkinson disease
levodopa 20 mg/mL + carbidopa monohydrate 5 mg/mL intestinal gel, 7 x 100 mL	11919H		Advanced Parkinson disease
levodopa 200 mg + benserazide 50 mg capsule, 100	2226E		
levodopa 200 mg + benserazide 50 mg tablet, 100	2228G		
levodopa 200 mg + carbidopa 50 mg + entacapone 200 mg tablet, 100	9292C		Parkinson disease
levodopa 200 mg + carbidopa 50 mg modified release tablet, 100	1255C		Parkinson disease
levodopa 200 mg + carbidopa 50 mg modified release tablet, 60	11890T		Parkinson disease
levodopa 250 mg + carbidopa 25 mg tablet, 100	1245M		
levodopa 50 mg + benserazide 12.5 mg capsule, 100	2227F		
levodopa 50 mg + benserazide 12.5 mg dispersible tablet, 100	8218M		
levodopa 50 mg + carbidopa 12.5 mg + entacapone 200 mg tablet, 100	8797B		Parkinson disease
levodopa 75 mg + carbidopa 18.75 mg + entacapone 200 mg tablet, 100	9344T		Parkinson disease
mianserin hydrochloride 10 mg tablet, 50	1627P		Severe depression
mianserin hydrochloride 20 mg tablet, 50	1628Q		Severe depression
mirtazapine 15 mg orally disintegrating tablet, 30	8855C		Major depressive disorders
mirtazapine 15 mg tablet, 30	9365X		Major depressive disorders
mirtazapine 30 mg orally disintegrating tablet, 30	8856D		Major depressive disorders

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
mirtazapine 30 mg tablet, 30	8513C		Major depressive disorders
mirtazapine 45 mg orally disintegrating tablet, 30	8857E		Major depressive disorders
mirtazapine 45 mg tablet, 30	8883M		Major depressive disorders
moclobemide 150 mg tablet, 60	1900B		Major depressive disorders
moclobemide 300 mg tablet, 60	8003F		Major depressive disorders
oxcarbazepine 150 mg tablet, 100	8584T		Seizures
oxcarbazepine 300 mg tablet, 100	8585W		Seizures
oxcarbazepine 60 mg/mL oral liquid, 250 mL	8588B		Seizures
oxcarbazepine 600 mg tablet, 100	8586X		Seizures
paroxetine 20 mg tablet, 30	2242B		M - Major depressive disorders, Obsessive-compulsive disorder, Panic disorder
perampanel 10 mg tablet, 28	10151G		Intractable partial epileptic seizures
perampanel 10 mg tablet, 28	11428L		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
perampanel 12 mg tablet, 28	10159Q		Intractable partial epileptic seizures
perampanel 12 mg tablet, 28	11409L		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
perampanel 4 mg tablet, 28	10162W		Intractable partial epileptic seizures
perampanel 6 mg tablet, 28	10163X		Intractable partial epileptic seizures
perampanel 8 mg tablet, 28	10160R		Intractable partial epileptic seizures
perampanel 8 mg tablet, 28	11429M		Idiopathic generalised epilepsy with primary generalised tonic-clonic seizures
phenelzine 15 mg tablet, 100	2856H		Depression
phenelzine 15 mg tablet, 60	12239E		Depression
phenytoin 30 mg/5 mL oral liquid, 500 mL	2692Q		
phenytoin 50 mg chewable tablet, 200	1249R		
phenytoin sodium 100 mg capsule, 200	1874P		
phenytoin sodium 30 mg capsule, 200	1873N		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
pizotifen 500 microgram tablet, 100	3074T		
pramipexole dihydrochloride monohydrate 1 mg tablet, 100	9153R		Parkinson disease
pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet, 30	3420B		Parkinson disease
pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet, 30	5143Q		Parkinson disease
pramipexole dihydrochloride monohydrate 250 microgram tablet, 100	9152Q		Parkinson disease
pramipexole dihydrochloride monohydrate 3 mg modified release tablet, 30	3421C		Parkinson disease
pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet, 30	5145T		Parkinson disease
pramipexole dihydrochloride monohydrate 375 microgram modified release tablet, 30	3418X		Parkinson disease
pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet, 30	3422D		Parkinson disease
pramipexole dihydrochloride monohydrate 750 microgram modified release tablet, 30	3419Y		Parkinson disease
pyridostigmine bromide 10 mg tablet, 50	2724J		
pyridostigmine bromide 180 mg modified release tablet, 50	2608G		
pyridostigmine bromide 60 mg tablet, 150	1959D		
rasagiline 1 mg tablet, 30	1952R		Parkinson disease
reboxetine 4 mg tablet, 60	8583R		Major depressive disorders
riluzole 50 mg tablet, 56	8664B		Amyotrophic lateral sclerosis
riluzole 50 mg/10 mL oral liquid, 300 mL	11662T		Amyotrophic lateral sclerosis
rotigotine 2 mg/24 hours patch, 28	2385M		Parkinson disease
rotigotine 4 mg/24 hours patch, 28	2384L		Parkinson disease
rotigotine 6 mg/24 hours patch, 28	2410W		Parkinson disease
rotigotine 8 mg/24 hours patch, 28	11140H		Parkinson disease

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
safinamide 100 mg tablet, 30	11666B		Parkinson disease
safinamide 50 mg tablet, 30	11656L		Parkinson disease
selegiline hydrochloride 5 mg tablet, 100	1973W		Late stage Parkinson disease
sertraline 100 mg tablet, 30	2237R		Major depressive disorders
sertraline 100 mg tablet, 30	8837D		M - Obsessive-compulsive disorder, Panic disorder
sertraline 50 mg tablet, 30	2236Q		Major depressive disorders
sertraline 50 mg tablet, 30	8836C		M - Obsessive-compulsive disorder, Panic disorder
sulthiame 200 mg tablet, 200	2100M		
sulthiame 50 mg tablet, 200	2099L		
tetrabenazine 25 mg tablet, 112	1330B		Hyperkinetic extrapyramidal disorders
tiagabine 10 mg tablet, 50	8222R		Partial epileptic seizures
tiagabine 15 mg tablet, 50	8223T		Partial epileptic seizures
tiagabine 5 mg tablet, 50	8221Q		Partial epileptic seizures
topiramate 100 mg tablet, 60	8165R		Migraine, Seizures
topiramate 15 mg capsule, 60	8371N		Seizures
topiramate 200 mg tablet, 60	8166T		Seizures
topiramate 25 mg capsule, 60	8372P		Seizures
topiramate 25 mg tablet, 60	8163P		Migraine, Seizures
topiramate 50 mg capsule, 60	8520K		Seizures
topiramate 50 mg tablet, 60	8164Q		Migraine, Seizures
tranylcypromine 10 mg tablet, 50	2444P		
valproate sodium 100 mg tablet, 100	2294R		
valproate sodium 200 mg enteric tablet, 100	2289L		
valproate sodium 200 mg/5 mL oral liquid, 300 mL	2293Q		
valproate sodium 200 mg/5 mL oral liquid, 300 mL	2295T		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
valproate sodium 500 mg enteric tablet, 100	2290M		
venlafaxine 150 mg modified release capsule, 28	8302Y		Major depressive disorders
venlafaxine 75 mg modified release capsule, 28	8301X		Major depressive disorders
vigabatrin 500 mg powder for oral liquid, 60 sachets	2668K		Epileptic seizures
vigabatrin 500 mg tablet, 100	2667J		Epileptic seizures
zonisamide 100 mg capsule, 56	9390F		Partial epileptic seizures
zonisamide 25 mg capsule, 56	9388D		Partial epileptic seizures
zonisamide 50 mg capsule, 56	9389E		Partial epileptic seizures

1.11 RESPIRATORY SYSTEM

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
aclidinium 322 microgram/actuation powder for inhalation, 60 actuations	10124W		Chronic obstructive pulmonary disease (COPD)
aclidinium 340 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 12 microgram/actuation powder for inhalation, 60 actuations	10565C		Chronic obstructive pulmonary disease (COPD)
beclometasone dipropionate 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation + glycopyrronium 10 microgram/actuation inhalation, 120 actuations	12468F		Chronic obstructive pulmonary disease (COPD)
beclometasone dipropionate 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation inhalation, 120 actuations	12183F		Asthma
beclometasone dipropionate 100 microgram/actuation breath activated inhalation, 200 actuations	8409N		Asthma
beclometasone dipropionate 100 microgram/actuation inhalation, 200 actuations	8407L		
beclometasone dipropionate 50 microgram/actuation breath activated inhalation, 200 actuations	8408M		Asthma
beclometasone dipropionate 50 microgram/actuation inhalation, 200 actuations	8406K		
budesonide 1 mg/2 mL inhalation solution, 30 x 2 mL ampoules	2066R		Severe chronic asthma
budesonide 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 3 microgram/actuation inhalation, 120 actuations	10015D		Asthma
budesonide 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 3 microgram/actuation inhalation, 120 actuations	12089G		Asthma

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
budesonide 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, 120 actuations	8796Y		Asthma
budesonide 100 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, 120 actuations	12101X		Asthma
budesonide 100 microgram/actuation powder for inhalation, 200 actuations	2070Y		
budesonide 160 microgram/actuation + glycopyrronium 7.2 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 5 microgram/actuation inhalation, 120 actuations	12672Y		Chronic obstructive pulmonary disease (COPD)
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation inhalation, 120 actuations	10018G		M - Asthma, Chronic obstructive pulmonary disease (COPD)
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation inhalation, 120 actuations	12082X		Asthma
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, 120 actuations	8625Y		Asthma
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, 120 actuations	11273H		Asthma
budesonide 200 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, 120 actuations	12093L		Asthma
budesonide 200 microgram/actuation powder for inhalation, 200 actuations	2071B		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
budesonide 400 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 12 microgram/actuation powder for inhalation, 2 x 60 actuations	8750M		M - Asthma, Chronic obstructive pulmonary disease (COPD)
budesonide 400 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 12 microgram/actuation powder for inhalation, 2 x 60 actuations	11301T		M - Asthma, Chronic obstructive pulmonary disease (COPD)
budesonide 400 microgram/actuation powder for inhalation, 200 actuations	2072C		
budesonide 50 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 3 microgram/actuation inhalation, 120 actuations	10024N		Asthma
budesonide 50 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 3 microgram/actuation inhalation, 120 actuations	12100W		Asthma
budesonide 500 microgram/2 mL inhalation solution, 30 x 2 mL ampoules	2065Q		Severe chronic asthma
ciclesonide 160 microgram/actuation inhalation, 120 actuations	8854B		
ciclesonide 80 microgram/actuation inhalation, 120 actuations	8853Y		
fluticasone furoate 100 microgram/actuation + umeclidinium 62.5 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, 30 actuations	11379X		Chronic obstructive pulmonary disease (COPD)
fluticasone furoate 100 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, 30 actuations	11124L		M - Asthma, Chronic obstructive pulmonary disease (COPD)
fluticasone furoate 100 microgram/actuation powder for inhalation, 30 actuations	11719T		
fluticasone furoate 200 microgram/actuation + umeclidinium 62.5 microgram/actuation +	12917W		Severe asthma

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
vilanterol 25 microgram/actuation powder for inhalation, 30 actuations			
fluticasone furoate 200 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, 30 actuations	11129R		Asthma
fluticasone furoate 200 microgram/actuation powder for inhalation, 30 actuations	11729H		
fluticasone propionate 100 microgram/actuation + salmeterol 50 microgram/actuation powder for inhalation, 60 actuations	8430Q		Asthma
fluticasone propionate 100 microgram/actuation powder for inhalation, 60 actuations	8147T		
fluticasone propionate 125 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 5 microgram/actuation inhalation, 120 actuations	10007Q		Asthma
fluticasone propionate 125 microgram/actuation + salmeterol 25 microgram/actuation inhalation, 120 actuations	8518H		Asthma
fluticasone propionate 125 microgram/actuation inhalation, 120 actuations	8345F		
fluticasone propionate 250 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 10 microgram/actuation inhalation, 120 actuations	10008R		Asthma
fluticasone propionate 250 microgram/actuation + salmeterol 25 microgram/actuation inhalation, 120 actuations	8519J		M - Asthma, Chronic obstructive pulmonary disease (COPD)
fluticasone propionate 250 microgram/actuation + salmeterol 50 microgram/actuation powder for inhalation, 60 actuations	8431R		Asthma
fluticasone propionate 250 microgram/actuation powder for inhalation, 60 actuations	8148W		
fluticasone propionate 50 microgram/actuation + formoterol (eformoterol) fumarate dihydrate 5 microgram/actuation inhalation, 120 actuations	2827T		Asthma

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
fluticasone propionate 50 microgram/actuation + salmeterol 25 microgram/actuation inhalation, 120 actuations	8517G		Asthma
fluticasone propionate 50 microgram/actuation inhalation, 120 actuations	8516F		
fluticasone propionate 500 microgram/actuation + salmeterol 50 microgram/actuation powder for inhalation, 60 actuations	8432T		M - Asthma, Chronic obstructive pulmonary disease (COPD)
formoterol (eformoterol) fumarate dihydrate 12 microgram powder for inhalation, 60 capsules	8136F		Asthma
formoterol (eformoterol) fumarate dihydrate 12 microgram/actuation powder for inhalation, 60 actuations	8240Q		Asthma
formoterol (eformoterol) fumarate dihydrate 6 microgram/actuation powder for inhalation, 60 actuations	8239P		Asthma
glycopyrronium 50 microgram powder for inhalation, 30 capsules	10059K		Chronic obstructive pulmonary disease (COPD)
indacaterol 110 microgram + glycopyrronium 50 microgram powder for inhalation, 30 capsules	10156M		Chronic obstructive pulmonary disease (COPD)
indacaterol 114 microgram + glycopyrronium 46 microgram + mometasone furoate 136 microgram powder for inhalation, 30 capsules	12295D		Severe asthma
indacaterol 114 microgram + glycopyrronium 46 microgram + mometasone furoate 68 microgram powder for inhalation, 30 capsules	12298G		Severe asthma
indacaterol 125 microgram + mometasone furoate 127.5 microgram powder for inhalation, 30 capsules	12289T		Asthma
indacaterol 125 microgram + mometasone furoate 260 microgram powder for inhalation, 30 capsules	12279G		Asthma

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
indacaterol 125 microgram + mometasone furoate 62.5 microgram powder for inhalation, 30 capsules	12269R		Asthma
indacaterol 150 microgram powder for inhalation, 30 capsules	5134F		Chronic obstructive pulmonary disease (COPD)
indacaterol 300 microgram powder for inhalation, 30 capsules	5137J		Chronic obstructive pulmonary disease (COPD)
montelukast 4 mg chewable tablet, 28	8627C		Asthma
montelukast 5 mg chewable tablet, 28	8628D		Asthma
salmeterol 50 microgram/actuation powder for inhalation, 60 actuations	8141L		Asthma
tiotropium 13 microgram powder for inhalation, 30 capsules	11892X		Chronic obstructive pulmonary disease (COPD)
tiotropium 18 microgram powder for inhalation, 30 capsules	8626B		Chronic obstructive pulmonary disease (COPD)
tiotropium 2.5 microgram/actuation + olodaterol 2.5 microgram/actuation inhalation solution, 60 actuations	10557P		Chronic obstructive pulmonary disease (COPD)
tiotropium 2.5 microgram/actuation inhalation solution, 60 actuations	10509D		M - Bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease
tiotropium 2.5 microgram/actuation inhalation solution, 60 actuations	11043F		Severe asthma
tiotropium 2.5 microgram/actuation inhalation solution, 60 actuations	11629C		Severe asthma
umeclidinium 62.5 microgram powder for inhalation, 30 actuations	10187E		Chronic obstructive pulmonary disease (COPD)
umeclidinium 62.5 microgram/actuation + vilanterol 25 microgram/actuation powder for inhalation, 30 actuations	10188F		Chronic obstructive pulmonary disease (COPD)

1.12 SENSORY ORGANS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
betaxolol 0.5% eye drops, 5 mL	2825Q		
betaxolol 0.5% eye drops, 5 mL	5544T		
bimatoprost 0.03% + timolol 0.5% eye drops, 3 mL	5558M		Elevated intra-ocular pressure
bimatoprost 0.03% + timolol 0.5% eye drops, 3 mL	9464D		Elevated intra-ocular pressure
bimatoprost 0.03% + timolol 0.5% eye drops, 30 x 0.4 mL unit doses	10107Y		Elevated intra-ocular pressure
bimatoprost 0.03% + timolol 0.5% eye drops, 30 x 0.4 mL unit doses	10108B		Elevated intra-ocular pressure
bimatoprost 0.03% eye drops, 3 mL	5551E		
bimatoprost 0.03% eye drops, 3 mL	8620Q		
bimatoprost 0.03% eye drops, 30 x 0.4 mL unit doses	10046R		
bimatoprost 0.03% eye drops, 30 x 0.4 mL unit doses	10053D		
brimonidine tartrate 0.15% eye drops, 5 mL	5298W		
brimonidine tartrate 0.15% eye drops, 5 mL	5563T		
brimonidine tartrate 0.2% + timolol 0.5% eye drops, 5 mL	5535H		Elevated intra-ocular pressure
brimonidine tartrate 0.2% + timolol 0.5% eye drops, 5 mL	8826M		Elevated intra-ocular pressure
brimonidine tartrate 0.2% eye drops, 5 mL	5534G		
brimonidine tartrate 0.2% eye drops, 5 mL	8351M		
brinzolamide 1% + brimonidine tartrate 0.2% eye drops, 5 mL	10536M		Elevated intra-ocular pressure
brinzolamide 1% + brimonidine tartrate 0.2% eye drops, 5 mL	10547D		Elevated intra-ocular pressure
brinzolamide 1% + timolol 0.5% eye drops, 5 mL	3438Y		Elevated intra-ocular pressure
brinzolamide 1% + timolol 0.5% eye drops, 5 mL	5562R		Elevated intra-ocular pressure
brinzolamide 1% eye drops, 5 mL	5540N		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
brinzolamide 1% eye drops, 5 mL	8483L		
carbomer-974P 0.3% eye gel, 30 x 500 mg unit doses	5502N		Severe dry eye syndrome
carbomer-974P 0.3% eye gel, 30 x 500 mg unit doses	8514D		Severe dry eye syndrome
carbomer-980 0.2% eye drops, 30 x 0.6 mL unit doses	5504Q		Severe dry eye syndrome
carbomer-980 0.2% eye drops, 30 x 0.6 mL unit doses	8578L		Severe dry eye syndrome
carbomer-980 0.2% eye gel, 10 g	5503P		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 0.5% + glycerol 0.9% eye drops, 15 mL	5556K		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 0.5% eye drops, 10 mL	11852T		Severe dry eye syndrome
carmellose sodium 0.5% eye drops, 10 mL	11853W		Severe dry eye syndrome
carmellose sodium 0.5% eye drops, 15 mL	5507W		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 0.5% eye drops, 30 x 0.4 mL unit doses	2338C		Severe dry eye syndrome
carmellose sodium 0.5% eye drops, 30 x 0.4 mL unit doses	5506T		Severe dry eye syndrome
carmellose sodium 1% eye drops, 15 mL	5508X		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 1% eye drops, 30 x 0.4 mL unit doses	2324H		Severe dry eye syndrome
carmellose sodium 1% eye drops, 30 x 0.4 mL unit doses	5505R		Severe dry eye syndrome
dextran-70 0.1% + hypromellose 0.3% eye drops, 15 mL	5520M		M - Severe dry eye syndrome, including Sjogren's syndrome
dextran-70 0.1% + hypromellose 0.3% eye drops, 28 x 0.4 mL unit doses	5521N		Severe dry eye syndrome
dextran-70 0.1% + hypromellose 0.3% eye drops, 28 x 0.4 mL unit doses	8299T		Severe dry eye syndrome

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
dorzolamide 2% + timolol 0.5% eye drops, 5 mL	5542Q		Elevated intra-ocular pressure
dorzolamide 2% + timolol 0.5% eye drops, 5 mL	8567X		Elevated intra-ocular pressure
dorzolamide 2% eye drops, 5 mL	5541P		
dorzolamide 2% eye drops, 5 mL	8488R		
fluorometholone 0.1% eye drops, 5 mL	1204J		
hyaluronate sodium 0.1% eye drops, 10 mL	2181T		Severe dry eye syndrome
hyaluronate sodium 0.1% eye drops, 10 mL	2184Y		Severe dry eye syndrome
hyaluronate sodium 0.2% eye drops, 10 mL	2171G		Severe dry eye syndrome
hyaluronate sodium 0.2% eye drops, 10 mL	2253N		Severe dry eye syndrome
hypromellose 0.3% + carbomer-980 0.2% eye gel, 10 g	5519L		M - Severe dry eye syndrome, including Sjogren's syndrome
hypromellose 0.3% w/v eye drops, 10 mL	11842G		Severe dry eye syndrome
hypromellose 0.3% w/v eye drops, 10 mL	11849P		Severe dry eye syndrome
hypromellose 0.3% w/w eye drops, 10 mL	11634H		M - Severe dry eye syndrome, including Sjogren's syndrome
hypromellose 0.5% eye drops, 15 mL	5517J		M - Severe dry eye syndrome, including Sjogren's syndrome
latanoprost 0.005% + timolol 0.5% eye drops, 2.5 mL	5553G		Elevated intra-ocular pressure
latanoprost 0.005% + timolol 0.5% eye drops, 2.5 mL	8895E		Elevated intra-ocular pressure
latanoprost 0.005% eye drops, 2.5 mL	5552F		
latanoprost 0.005% eye drops, 2.5 mL	8243W		
liquid paraffin + glycerol + tyloxapol + poloxamer-188 + trometamol hydrochloride + trometamol + cetalkonium chloride eye drops, 10 mL	12612T		Severe dry eye syndrome
paraffin 1 g/g eye ointment, 2 x 3.5 g	5522P		
paraffin 1 g/g eye ointment, 3.5 g	5523Q		
perfluorohexyloctane 100% eye drops, 3 mL	11439C		Severe dry eye syndrome

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
perfluorohexyloctane 100% eye drops, 3 mL	11446K		Severe dry eye syndrome
pilocarpine hydrochloride 1% eye drops, 15 mL	2595N		
pilocarpine hydrochloride 1% eye drops, 15 mL	5536J		
pilocarpine hydrochloride 2% eye drops, 15 mL	2596P		
pilocarpine hydrochloride 2% eye drops, 15 mL	5537K		
pilocarpine hydrochloride 4% eye drops, 15 mL	2598R		
pilocarpine hydrochloride 4% eye drops, 15 mL	5538L		
polyethylene glycol-400 0.4% + propylene glycol 0.3% eye drops, 15 mL	5524R		M - Severe dry eye syndrome, including Sjogren's syndrome
polyethylene glycol-400 0.4% + propylene glycol 0.3% eye drops, 28 x 0.8 mL unit doses	5532E		Severe dry eye syndrome
polyethylene glycol-400 0.4% + propylene glycol 0.3% eye drops, 28 x 0.8 mL unit doses	9170P		Severe dry eye syndrome
polyethylene glycol-400 0.4% + propylene glycol 0.3% eye drops, 30 x 0.8 mL unit doses	13100L		Severe dry eye syndrome
polyethylene glycol-400 0.4% + propylene glycol 0.3% eye drops, 30 x 0.8 mL unit doses	13113E		Severe dry eye syndrome
polyvinyl alcohol 1.4% eye drops, 15 mL	5526W		M - Severe dry eye syndrome, including Sjogren's syndrome
retinol palmitate 0.0138% + paraffin eye ointment, 5 g	2167C		
soy lecithin 1% + tocopherol 0.002% + vitamin A palmitate 0.025% spray, 100 actuations	5545W		Severe dry eye syndrome
soy lecithin 1% + tocopherol 0.002% + vitamin A palmitate 0.025% spray, 100 actuations	9448G		Severe dry eye syndrome
tafluprost 0.0015% eye drops, 30 x 0.3 mL unit doses	2748P		
tafluprost 0.0015% eye drops, 30 x 0.3 mL unit doses	2755B		
timolol 0.5% eye drops, 2.5 mL	1926J		
timolol 0.5% eye drops, 2.5 mL	5550D		

Pharmaceutical Benefits Advisory Committee (PBAC) December 2022 Meeting - New and Amended Listings for Increased Dispensing Quantities

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
timolol 0.5% eye drops, 5 mL	1279H		
timolol 0.5% eye drops, 5 mL	5548B		
travoprost 0.004% + timolol 0.5% eye drops, 2.5 mL	5555J		Elevated intra-ocular pressure
travoprost 0.004% + timolol 0.5% eye drops, 2.5 mL	9057Q		Elevated intra-ocular pressure
travoprost 0.004% eye drops, 2.5 mL	5554H		
travoprost 0.004% eye drops, 2.5 mL	8597L		

1.13 VARIOUS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
lanthanum 1 g chewable tablet, 6 x 15	9405B		Hyperphosphataemia
lanthanum 500 mg chewable tablet, 2 x 45	9403X		Hyperphosphataemia
lanthanum 750 mg chewable tablet, 6 x 15	9404Y		Hyperphosphataemia
phosphorus 500 mg effervescent tablet, 100	2946C		M - Familial hypophosphataemia, Hypercalcaemia, Hypophosphataemic rickets, Vitamin D-resistant rickets
sevelamer carbonate 800 mg tablet, 180	11856B		Hyperphosphataemia
sevelamer hydrochloride 800 mg tablet, 180	2142R		Hyperphosphataemia
sucroferric oxyhydroxide 2.5 g (iron 500 mg) chewable tablet, 90	10250L		Hyperphosphataemia

TABLE 2:

The following PBS medicines/item codes currently available under the *12 month repeat measure* were found suitable for amendment in accordance with the PBAC recommendations for increased dispensed quantities.

2.1 AMENDED LISTINGS

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
atorvastatin 10 mg tablet, 30	9230T		*
atorvastatin 20 mg tablet, 30	9231W		*
atorvastatin 40 mg tablet, 30	9232X		*
atorvastatin 80 mg tablet, 30	9233Y		*
carbomer-980 0.2% eye gel, 10 g	9210R		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 0.5% + glycerol 0.9% eye drops, 15 mL	9356K		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 0.5% eye drops, 15 mL	9211T		M - Severe dry eye syndrome, including Sjogren's syndrome
carmellose sodium 1% eye drops, 15 mL	9212W		M - Severe dry eye syndrome, including Sjogren's syndrome
colestyramine 4 g powder for oral liquid, 50 sachets	9249T		*
dextran-70 0.1% + hypromellose 0.3% eye drops, 15 mL	9216C		M - Severe dry eye syndrome, including Sjogren's syndrome
fenofibrate 145 mg tablet, 30	9247Q		*
fenofibrate 48 mg tablet, 60	9246P		*
fluvastatin 80 mg modified release tablet, 28	9236D		*
gemfibrozil 600 mg tablet, 60	9248R		*
hypromellose 0.3% + carbomer-980 0.2% eye gel, 10 g	9215B		M - Severe dry eye syndrome, including Sjogren's syndrome
hypromellose 0.3% w/w eye drops, 10 mL	11643T		M - Severe dry eye syndrome, including Sjogren's syndrome
hypromellose 0.5% eye drops, 15 mL	9214Y		M - Severe dry eye syndrome, including Sjogren's syndrome

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
pancreatic extract 10 000 units modified release capsule, 100	9226N		Cystic fibrosis
pancreatic extract 25 000 units modified release capsule, 100	9227P		Cystic fibrosis
pancreatic extract 35 000 units modified release capsule, 100	12578B		Cystic fibrosis
pancreatic extract 5000 units/100 mg enteric coated granules, 20 g	5454C		Cystic fibrosis
pancrelipase 25 000 units capsule, 100	12933Q		Cystic fibrosis
pancrelipase 25 000 units capsule, 100	9229R		Cystic fibrosis
paraffin 1 g/g eye ointment, 2 x 3.5 g	9218E		*
paraffin 1 g/g eye ointment, 3.5 g	9217D		*
polyethylene glycol-400 0.4% + propylene glycol 0.3% eye drops, 15 mL	9219F		M - Severe dry eye syndrome, including Sjogren's syndrome
polyvinyl alcohol 1.4% eye drops, 15 mL	9220G		M - Severe dry eye syndrome, including Sjogren's syndrome
pravastatin sodium 10 mg tablet, 30	9237E		*
pravastatin sodium 20 mg tablet, 30	9238F		*
pravastatin sodium 40 mg tablet, 30	9239G		*
pravastatin sodium 80 mg tablet, 30	9240H		*
retinol palmitate 0.0138% + paraffin eye ointment, 5 g	2202X		*
rosuvastatin 10 mg tablet, 30	2584B		*
rosuvastatin 20 mg tablet, 30	2609H		*
rosuvastatin 40 mg tablet, 30	2636R		*
rosuvastatin 5 mg tablet, 30	2590H		*
simvastatin 10 mg tablet, 30	9242K		*
simvastatin 20 mg tablet, 30	9243L		*
simvastatin 40 mg tablet, 30	9244M		*
simvastatin 5 mg tablet, 30	9241J		*
simvastatin 80 mg tablet, 30	9245N		*

Medicine (strength & form)	Item Code	Brand	Indication (M=multiple, blank=Unrestricted)
sulfasalazine 500 mg enteric tablet, 100	9209Q		*
sulfasalazine 500 mg tablet, 100	9208P		*

*The current PBS restrictions for these items include the criteria: *for use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.*